Brought to you by 
Israeli CNS company Alcobra completes $23.3mm US IPO
23 May 2013
Executive Summary
Alcobra Ltd. (therapeutics for cognitive dysfunction disorders) netted $23.3mm in its US initial public offering. The Israeli firm sold 3.1mm ordinary shares--more than the 2.3mm planned--for $8, a haircut against the anticipated $10-12 price range.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Israeli CNS company Alcobra completes $23.3mm US IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice